See original release here

March 22, 2017 [OTTAWA] – Canada’s biotech industry today welcomed the federal budget and its measures supporting the advancement of Canadian innovation in biotechnology centered sectors such as health/bio-sciences, clean technology and agri-food. Importantly the budget proposes support for the acceleration of innovation through the establishment of sector specific superclusters, including health/bio-sciences, agri-food and clean technology.

“The core of our industry is innovation – much of it coming out of universities. The Budget’s focus on innovation and creating super clusters in biotechnology centered fields including health/bio-sciences, agri-food, and clean technology recognizes Canada’s strengths in these areas and the enormous opportunity for the economy in successfully advancing biotechnology innovation. Today’s commitments will result in products and therapies of the future and will accelerate the use of biotechnology in supporting the global competitiveness of Canada’s traditional cornerstone economic sectors of agriculture, forestry, mining, energy and advanced manufacturing,” commented Andrew Casey, President and CEO BIOTECanada.

Drawing on the nation’s rich legacy of research, Canada now has an opportunity to become one of the world’s most successful modern biotech regions by transitioning its traditional industries into the new economy while drawing on its considerable strength of its investment in research. From universities, small mid-sized companies, hospitals and public research agencies across the country, Canadian biotech scientists make up the ecosystem ensuring Canada’s biotechnology sector thrive.

Importantly, Canada already has in place many of the components necessary for global competitiveness and success in biotechnology. Indeed, Canada is home to a number of regional clusters which bring together: world-class universities and research institutes; biotech entrepreneurs; a significant multinational industry presence; and, a highly educated workforce. All told, the Canadian national biotech ecosystem is an economic strength that positions Canada well to compete in the emerging global bio-economy. The Budget will help harness many of these strengths to accelerate Canada’s biotechnology innovation progress.

BIOTECanada looks forward to working with the federal government over the months ahead, offering a coordinated set of recommendations and mechanisms for the announced programs. Implementation consultations are key to ensuring the commitments realize the potential they offer to the biotechnology industry.

For more information

Nadine Lunt
613-230-5585 x257

Working to improve diagnosis and treatment for patients with diabetic retinopathy

Nearly 90 percent of people living with diabetes will eventually go blind. Diabetic retinopathy is caused by diseased vessels in the retina leaking blood components or hemorrhaging.  The affects increasingly distort vision because of scarring of the retina and, in its most advanced stage, leads to blindness. The damage is irreparable increasing the importance of early diagnosis.

The current diagnostic procedure is Fluorescein Angiography, a standard eye test performed by an ophthalmologist, who uses a special dye and camera to look at blood flow in the retina. The ophthalmologist visually reads the images and provides a diagnosis based on qualitative analysis.  The founder of Emagix, Dr. Alon Friedman together with his team, developed software that reduces the testing time while enhancing the current images and providing results that enable a quantitative analysis. The software uses an algorithm that processes multiple images to produce a single, finer grain image, which makes previously imperceptible leaks from tiny capillaries as noticeable as much larger leaks from bigger vessels.  In short, this innovation promises to reduce the subjectivity involved in reading the test results dramatically.  Additionally, this process will enable much more precise and objective analysis of treatment effectiveness.

Dr. Friedman moved his research to Dalhousie University from Ben-Gurion University in Israel in 2014 after being attracted to the university and the province of Nova Scotia because of its business community and provincial support from organizations such as ACOA, Innovacorp and BioNova.  The gain was also a big one for Dalhousie, Dr. Friedman is one of the top researchers globally in his field and has received over $9 million in research funding over the past decade.

The software can be integrated into existing equipment and will provide ophthalmologists with much more valuable data that promises to significantly improve diagnosis and treatment efficacy not only for patients at risk of diabetic retinopathy but also patients with Alzheimer’s Disease, Stroke, brain injuries and other diseases that are caused by leakage from blood vessels.

Revolutionizing the way people are repositioned in wheelchairs in homes, hospitals and care facilities around the world.

Nova Scotians working in the healthcare sector have the highest rate of workplace injury compared to any other industry, with musculoskeletal injuries to healthcare workers costing Nova Scotia taxpayers $100 million annually. These injuries are frequently caused by continuing care workers repositioning patients in wheelchairs who are unable to reposition themselves.

MacKenzie Healthcare Technologies, in collaboration with NSCC and Northwood, a leading long-term care facility in Halifax, has developed The Paraglide system to help alleviate this problem. Paraglide is a wheelchair repositioning system that brings mechanical innovation to the currently injury-prone and undignified task of moving someone in a wheelchair from a slouched position to an upright position.

The Paraglide device will be the first of its kind that will allow people who become slouched forward in wheelchairs to reposition themselves at the touch of a button, removing the reliance of a caregiver and giving them dignity and independence. The device will also eliminate the risk of caregiver injury for this task, prevent pressure injuries (bed sores), and save resources in healthcare facilities, nursing homes, homecare, governments and injury-related insurance coverage for both wheelchair users and caregivers alike.

Paraglide, made of lightweight aluminum, contains a motor, gears, and electronics which attach to the back of the wheelchair. The device uses a wireless remote control, rotating and pulling a specially designed fabric sheet along the seat of the wheelchair thereby moving the person automatically. When the button is released the device releases the sheet, allowing enough slack for the individual to make their way forward again, allowing free movement.

Last October, MacKenzie Healthcare Technologies was named the winner of the sixth annual BioInnovation Challenge (Presented by BioNova) chosen by a panel of judges for its adaptability, market pull, and consumer readiness. The prize package valued at more than $30,000, contained a seed investment and a package of advisory services that the company has used to advance its production as it prepares for the market this summer.

See original release here

Government of Canada supports research and development of miniature probe for medical application

Development of an imaging and tissue cutting probe for guided neuro surgeries is expected to improve patient survival rates and create 12 highly-skilled positions in Nova Scotia’s life sciences sector. This includes nine placements for graduate students to help them access the innovative jobs of today and tomorrow.
The miniature endoscope uses ultrasound for both imaging and precision cutting during surgery. Small enough for surgeons to insert into the brain through a small hole, it will assist in the diagnosis and treatment of serious conditions such as blood clots and brain tumors. It also has application in minimally invasive cardiac procedures.
The Government of Canada is making a $2,685,540 investment over five years in the Nova Scotia Health Authority (NSHA) to develop a miniature endoscope prototype.
The federal funding was announced today by Darrell Samson, Member of Parliament for Sackville-Preston-Chezzetcook, on behalf of the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for the Atlantic Canada Opportunities Agency (ACOA).
Canadian-based Synaptive Medical Inc. and Conavi Medical Inc. are each providing $250,000 in cash and $150,000 of in-kind support to assist with the development of this advanced ultrasound technology. The NSHA will license the prototype to Synaptive Medical Inc. who intends to bring the device through the regulatory process and commercialize it for surgical applications, including neuro surgery. Conavi Medical will use the device for cardiovascular applications.
Canada’s Innovation Agenda aims to make this country a global centre for innovation—one that creates jobs, drives growth across all industries and improves the lives of all Canadians‎. The Government of Canada’s investment is provided through ACOA’s Atlantic Innovation Fund. The Atlantic Innovation Fund encourages partnerships among private sector firms, universities, colleges and other research institutions to develop and commercialize new or improved products and services in Atlantic Canada.


“The work of the Nova Scotia Health Authority exemplifies Canada’s readiness to participate in the global innovation race, competing with countries around the world for the most talented people, the newest technologies and the fastest-growing companies. That is why the Government of Canada is committed to supporting projects such as this, which enhance Atlantic Canada’s ability to compete in the global marketplace.”

The Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for ACOA


“Nova Scotia’s life sciences sector is thriving due to our R&D capabilities and highly trained individuals. It is innovation like this that provides high quality jobs for our educated workforce, helping to attract and retain talent in the region. The NSHA is setting the bar internationally for excellence in hi-resolution ultrasound technology, creating economic spinoffs right here at home.”

Darrell Samson, Member of Parliament for Sackville-Preston-Chezzetcook


“I think the impact of this investment will happen in two areas: it will lead to healthcare technology that will improve cancer diagnostics and therapeutics within the brain; and, it will also have a significant economic impact as we are currently developing some of the most advanced ultrasound technology in the world. Moving ahead, we are excited to work with international leaders in life sciences R&D, such as Synaptive Medical and Conavi Medical.”

Dr. Jeremy Brown, Associate Professor, Depts. of Biomedical Engineering and Electrical Engineering, Dalhousie University; and, Affiliated Scientist, Nova Scotia Health Authority


“As a medical device and technology company based in Toronto, Synaptive welcomes opportunities to work with industry and research partners across Canada. Partnering with the Nova Scotia Health Authority and Conavi Medical presents an exciting opportunity to leverage our expertise in surgery, ultrasound and medical imaging while developing a product that stands to benefit patients in Canada and around the world.”

Cameron Piron, President and Co-Founder, Synaptive Medical Inc.


“Dr. Brown and his team in Halifax have a strong track record of developing world-leading medical technologies that will provide benefits to patients by enabling precision guided treatments for complex conditions that impact both quality and quantity of life. Conavi Medical and Synaptive Medical are examples of Canadian scale-up companies that are demonstrating how Canada is evolving from a primary consumer of medical technologies, to an emerging provider of advanced solutions for patients and healthcare providers around the world.”

Dr. Brian Courtney, Executive Chairman, Conavi Medical Inc., Assistant Professor, Dept. of Medicine, University of Toronto and Clinician-Scientist, Sunnybrook Health Sciences Centre

Quick Facts

  • ACOA’s innovation programming, which includes the Atlantic Innovation Fund (AIF) and the Business Development Program (BDP), is designed to help bring to market new products, technologies and services that will improve the competitiveness and productivity of the Atlantic economy.
  • In any given year, approximately 296 Nova Scotia Health Authority researchers are engaged in more than 1,300 research projects. This translates into about $28M in annual research revenues and provides support to more than 360 dedicated research personnel positions, including 150 experienced research coordinators.
  • In any given year, approximately 296 Nova Scotia Health Authority researchers are engaged in more than 1,300 research projects. This translates into about $28M in annual research revenues and provides support to more than 360 dedicated research personnel positions, including 150 experienced research coordinators.

For Immediate Release

February 17, 2017 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc.(“Appili”), an anti-infective drug development company, announced today that it will be receiving $2,803,148 from the Atlantic Canada Opportunities Agency (ACOA), under the Atlantic Innovation Fund (AIF). This funding will enable Appili to take its first drug, ATI-1501 – a taste-masked, oral antibiotic that treats anaerobic infections like Clostridium difficile – through clinical trials to be ready for market approval.

“Having ACOA recognize the potential of our antibiotic reformulation to become a new weapon against anaerobic infections is outstanding,” said Kevin Sullivan, CEO of Appili Therapeutics. “This AIF funding supports our strategy to advance ATI-1501 into human clinical trials as soon as possible.”

Appili plans to take the antibiotic into clinical trials this year and is presently manufacturing the clinical batch of ATI-1501 to good manufacturing practices (GMP), the standard required by the Health Canada and the U.S. Food and Drug Administration (FDA).

ATI-1501 is a reformulation of metronidazole, a front-line treatment for anaerobic bacterial infections, including C. difficile.  Over 10 million metronidazole prescriptions are issued in the U.S. annually.

The bitter taste of the metronidazole tablets results in poor patient compliance, which leads to the spread of infections and recurrent infections within the patients.  In particular, reluctance to complete the prescribed course of antibiotics is highly problematic among children and the elderly with swallowing issues, who must crush and re-suspend tablets to ingest the metronidazole.

ATI-1501 has been optimized to improve palatability, which should significantly reduce issues with non-compliance. Once ingested, ATI-1501 kills anaerobic bacteria by interfering with their DNA, leading to bacterial cell death and clears up the infection.

About Appili Therapeutics

Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501 is a taste-masked treatment for anaerobic infections, including C. difficile. Appili’s second product, ATI-1503, is a novel antibiotic with broad potential to treat deadly Gram-negative infections such as Klebsiella pneumoniae. These drug-resistant infections have been identified by the U.S. Center for Disease Control (CDC) as posing the highest threat to human health. For more information visit


Media Relations Contact: Investor Relations Contact:
Jennifer Cameron Kevin Sullivan, CEO, Appili Therapeutics
T: 902-209-4704 E:


See original release here

HALIFAX, Nova Scotia – February 14, 2017 — Kinduct Technologies, a data and analytics software provider, and Athletigen Technologies Inc., a leader in proprietary human performance insights and genetic analytics provider, today announced that Kinduct’s software platform will soon incorporate Athletigen’s genetic insights.

“The partnership with Kinduct is an exciting opportunity, with both companies focused on pushing the limits of human performance, ” says Athletigen CEO, Dr. Jeremy Koenig. “Clients will now have access to genetic markers combined with performance data, biometric scores and subjective inputs to provide a comprehensive view of the athlete to help understand and improve their in-game performance.”

Athletigen’s proprietary platform analyzes an athlete’s DNA to empower coaches and athletes with actionable insights to inform peak performance in training and competition. The Kinduct platform enables organizations to analyze athlete data collected from different sources and then use those insights to inform decisions and drive continuous improvement in human performance.

Koenig added, “Each athlete is made for greatness, and we are one step in the journey to harnessing their maximum potential.”

“Athletigen analyses genetic markers that help athletes understand where their performance strengths and weaknesses truly lie,” says Dr. Travis McDonough, Kinduct Founder and CEO. “The partnership with Athletigen and the integration of their genetic insights into Kinduct’s platform will create a powerful tool for assessing an athlete’s condition and defining the optimal training and recovery programs.”

Kinduct’s technology platform, currently used by teams in the NHL, MLB, NFL, NBA, MLS, and NCAA allows for a two-way information exchange between coaches and athletes. Their Athlete Management System (AMS) gives teams the ability to collect, analyze, and act upon a wide range of player performance data and content such as training results, sleep schedules, maximum acceleration, deceleration, and heart rate. All of the information captured or calculated within the Kinduct platform supports informed decisions on personalized training and injury recovery programs for every athlete. This new partnership with Athletigen adds genetics as an important new layer of data.

“We see this combination of performance data and genetics as an important step in maximising player performance while reducing injury risk,” says McDonough. “Our clients can gain access to each athlete’s genetic foundation to better explain the data we capture.”


About Athletigen

Athletigen is a leader in proprietary human performance insights and genetic analytics. In 2016, Athletigen launched Iris™, the first of its kind, a personalized performance genomics app suite that merges an athlete’s genetic predispositions with daily monitoring data, empowering coaches and athletes with actionable insights. The evolution of our product is driven by intense user research conducted with world class, Olympic and Paralympic athletes. Through genomic innovation with strategic partners, Athletigen works to deliver the most advanced research findings in human performance to its customers.

About Kinduct

Kinduct is a leading data and analytics software provider. Kinduct’s highly secure, cloud-based platform allows human performance and sports organizations to spend less time managing their data and more time using it to inform decisions, promote constant improvement and produce exceptional results. Kinduct’s Athlete Management System is integrated with the best and brightest companies in the wearables, assessment and data collection sector. Kinduct is the software provider of choice for many professional and elite level sport organizations in the NFL, NBA, MLB, NHL, MLS and other professional or elite leagues. Kinduct’s investors include Intel Capital, CFFI Ventures Inc., and Elysian Park Ventures.

Media Contacts:


Bryce Crosby
T: 902.440.2957


Sean Williams
T: 902.220.5945

See full story by Sara Ericsson in Queens County Advance

CORNWALLIS, N.S. – Nova Scotia’s provincial government has announced funding for internships in research and innovation aimed at creating work opportunities for Nova Scotia students and companies.

It was announced Feb. 6 at Acadian Seaplants in Cornwallis that $705,000 in funding will create 170 internships over the next three years. Sixty of these internships will take place at Acadian Seaplants, in partnership with Dalhousie University and the Mitacs Accelerate Program.

The company, which processes seaweed to create products for numerous agricultural and chemical uses, has a long history of partnering with researchers to deliver cutting-edge products.

President and CEO JP Deveau said his company “sees research as a way of life,” and that partnerships between industry, government and research institutions are key to “working together to create technologies we can export around the world.”

Kelly Regan, Minister of Labour and Advanced Education, also attended Monday’s event, speaking about creating opportunities for recent university graduates.

“Hiring people that we invest in early… will help create a better Nova Scotia,” she said.

Original Press Release

University Health Network (UHN) in Toronto to Launch Triple-Combination Study Evaluating the Potential for Enhanced Anti-Cancer Activity of Currently Marketed Checkpoint Inhibitor When Combined with DPX-Survivac

 Halifax, Nova Scotia; February 6, 2017 – Immunovaccine Inc. (TSX: IMV; OTCQX: IMMVF), a clinical stage immuno-oncology company, today announced that the UHN’s Princess Margaret Cancer Centre (PM) will conduct a Phase 2 clinical trial to evaluate the use of a combination of immunotherapies from Immunovaccine and Merck (known as MSD outside the United States and Canada).

Clinical investigators will assess the safety and efficacy of Immunovaccine’s DPX-Survivac cancer vaccine candidate in combination with Merck’s checkpoint inhibitor Pembrolizumab in patients with recurrent, platinum-resistant ovarian cancer. Study participants will also receive metronomic cyclophosphamide, which is a low-dose regimen with immuno-modulating effects. PM listed the trial on and expects to initiate active enrollment following completion of the contract between Immunovaccine and UHN, and pending regulatory clearance from Health Canada.

“Ovarian cancer is a main focus for Immunovaccine as we continue to develop DPX-Survivac,” said Frederic Ors, Immunovaccine’s Chief Executive Officer.  “Combination therapies — particularly those with anti-PD-1 activity — are emerging as increasingly promising approaches for hard-to-treat cancers. We believe that the robust immunogenic and safety clinical profile for DPX-Survivac, along with its unique complementary activity to anti-PD-1 agents, which may boost their response rates, position our immuno-oncology candidate as an optimal co-therapy in this disease area.”

The non-randomized, open-label trial is designed to evaluate the potential anti-tumor activity of the combination of Pembrolizumab, DPX-Survivac, and low-dose cyclophosphamide. It is expected to enroll 42 subjects with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. The study’s primary objective is to assess overall response rate (ORR). Secondary study objectives include progression free survival (PFS) rate, overall survival (OS) rate, and potential side effects, over a five-year period.

 Amit M. Oza, Bsc (Hons), MBBS (Lon), MD (Lon), FRCPC, FRCP, Senior Staff Physician and Associate Professor of Medicine at PM is the lead investigator. Merck is funding this study and contributing materials. Immunovaccine is also contributing its product candidate as well as a related portion of analytical assays.

“Ovarian cancer is among the most challenging cancers to treat, as it is associated with poor response rates to currently available medical interventions,” said Dr. Oza. “To support the tens of thousands of women battling this disease, we need to develop new and novel approaches. With this trial, we have the opportunity to explore a novel combination of promising immunotherapies.”

DPX-Survivac is Immunovaccine’s lead immuno-oncology candidate, generated by its novel proprietary DepoVax™ adjuvanting technology platform. The DPX-Survivac target, survivin, is present in more than 20 types of solid tumor and hematologic cancers. It is involved in multiple critical pathways of cancer cell growth and survival. Prior results from a Phase 1/1b study indicated that DPX-Survivac combined with a low dose of cyclophosphamide was highly immunogenic in individuals with high-risk ovarian cancer, inducing survivin- specific T cell immune responses in most trial participants.

The company has shown in other studies that a combination immunotherapy using a DepoVax™-based vaccine could enhance the anti-tumor effects of a PD-1 blockade. Even tumors previously non-responsive to treatment with anti-PD-1 agents alone exhibited controlled cancer growth when combined with Immunovaccine’s DepoVax™-based compound.

In addition to this Phase 2 trial, Immunovaccine is conducting a Phase 1b trial with Incyte Corporation to evaluate the triple combination of DPX-Survivac with Incyte’s investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, Epacadostat (INCB24360), and low-dose oral cyclophosphamide in patients with platinum sensitive or resistant ovarian cancer. Immunovaccine expects to announce top-line interim results for this Phase 1b trial by the end of March 2017.

About DPX-Survivac

DPX-Survivac consists of survivin-based peptide antigens formulated in the DepoVax™ adjuvanting platform. The National Cancer Institute (NCI) has recognized survivin as a promising tumor-associated antigen (TAA) because of its therapeutic potential and its cancer specificity. Survivin is broadly over-expressed in multiple cancer types in addition to ovarian cancer, including breast, colon and lung cancers. Survivin plays an essential role in antagonizing cell death, supporting tumor-associated angiogenesis, and promoting resistance to anti-cancer therapies. Survivin is also a prognostic factor for many cancers and it is found in a higher percentage of tumors than other TAA’s.

The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T-cell immune response against cells presenting survivin peptides. This targeted therapy attempts to use the immune system to search actively and specifically for tumor cells and destroy them. Survivin-specific T-cells have been shown to target and kill survivin-expressing cancer cells while sparing normal cells.

DPX-Survivac received Fast Track designation by the FDA as maintenance therapy in individuals with advanced ovarian, fallopian tube, and peritoneal cancer who have no measureable disease following surgery and front-line platinum/taxane chemotherapy to improve their progression-free survival. The FDA also granted orphan drug status to DPX-Survivac for the treatment of ovarian cancer. This designation is valid for all applications of DPX-Survivac in ovarian cancer without restriction to a specific stage of disease.


About the Princess Margaret Cancer Centre of the Toronto Hospital

 The Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital, Toronto Rehabilitation Institute and the Michener Institute for Education; all affiliated with the University of Toronto. For more information, go to or

About Immunovaccine

Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented delivery agent that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer, as well as a Phase 2 study in recurrent lymphoma. The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and currently has clinical projects ongoing to assess the potential of DepoVax™ to address malaria and the Zika virus. Connect at


Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.


 Contacts for Immunovaccine:
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E:
Frederic Ors, Chief Executive Officer
T: (902) 492-1819 E: 

See original release

January 6, 2017 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc. (“Appili”), an anti-infective drug development company, announced today that Stephen Nicolle has been appointed to its Board of Directors. A seasoned executive, Mr. Nicolle has led companies to deliver innovative customer value and returned over $100 million to their investors.

“When it comes to leading venture-backed companies, Mr. Nicolle brings unparalleled business expertise and vision that will be instrumental as we grow and develop our pipeline of anti-infective products,” said Kevin Sullivan, CEO of Appili Therapeutics.

“I am attracted by Appili’s strategic approach of acquiring and developing early stage and late stage products which uniquely address the global demand for new antibiotic treatments to combat bacterial resistance,” said Stephen Nicolle, board director of Appili Therapeutics.  “I am honoured to join Appili’s board and look forward to making a contribution to this ambitious and exciting start-up company.”

Mr. Nicolle has 20 years of experience leading companies and growing shareholder value.  He is currently president of Cape Bear Advisors where he consults and holds numerous board positions, including vice chair of the start-up accelerator Propel ICT. Mr. Nicolle is the former CEO of leading healthcare technology company, STI Technologies, where he negotiated agreements with top pharmaceutical companies resulting in an increase in revenue of 500 per cent.  Before STI Technologies Mr. Nicolle spent 10 years leading venture-backed technology companies, including: CEO of Tatara Systems, CEO of Sigma Systems, COO at March Networks, and President of Nortel’s Service Provider eBusiness Solutions Group. He is a graduate of Western University with an honours degree in computer science.

Mr. Sullivan makes this announcement as he heads to San Francisco, where the life science industry’s largest investor conference, the JP Morgan Healthcare conference, is being held.

About Appili Therapeutics Inc.

Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The Company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501, a taste-masked treatment for anaerobic infections, including Clostridium difficile, has been granted orphan drug status by the FDA. Appili plans to take ATI-1501 into clinical trials in 2017. Appili’s second product, ATI-1503, is a novel antibiotic with broad potential to treat deadly Gram-negative infections such as Klebsiella pneumoniae. These drug-resistant infections have been identified by the U.S. Center for Disease Control (CDC) as posing the highest threat to human health. For more information visit

Media Relations Contact:

Jennifer Cameron

T: 902-209-4704


See original release here

December 21, 2016 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc. (“Appili”), an anti-infective drug development company, announced today it raised $2,151,000 in its over-subscribed private placement financing. Participants in this capital raise included current Appili investors such as Innovacorp, as well as new individual and institutional investors. Proceeds from the financing will be used to advance its lead product candidate, a taste-masked antibiotic designed to treat anaerobic infections like Clostridium difficile, into clinical trials. In addition, the Company will advance the development of a novel class of antibiotics targeting drug-resistant Gram-negative bacteria and evaluate opportunities to add high potential anti-infective programs to its pipeline.

“We appreciate the support and confidence our investors have in our strategy to build a pipeline of products that fit with our balanced-risk portfolio approach,” said Kevin Sullivan, CEO of Appili Therapeutics. “We continue to seek new programs that complement this balanced-risk approach with a mix of near-term revenue programs along with early stage programs that have the potential to fundamentally change how we treat infectious disease.”

“In a very short period of time, Appili has made significant progress with their strategy to identify and develop improved anti-infective therapies, and we look forward to supporting their upcoming clinical trial,” said Dr. Lidija Marušić, life sciences investment manager at Innovacorp, Nova Scotia’s early stage venture capital organization, and member of Appili’s Board of Directors.

“We are thrilled by the strong investor interest in this financing, which validates Appili’s strategy, science and development programs,” said Brian Bloom, president of Bloom Burton & Co., a healthcare-specialized investment bank, and chair of Appili’s Board of Directors.

About Appili Therapeutics

Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The Company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501, a taste-masked treatment for anaerobic infections, has been granted orphan drug status by the FDA. Appili plans to take ATI-1501 into clinical trials in 2017. Appili’s second product, ATI-1503, is a novel antibiotic with broad potential to treat deadly Gram-negative infections such as Klebsiella pneumoniae. These drug-resistant infections have been identified by the U.S. Center for Disease Control (CDC) as posing the highest threat to human health. For more information visit


Media Relations Contact: Investor Relations Contact:
Jennifer Cameron Kevin Sullivan, CEO, Appili Therapeutics
T: 902-209-4704 E:

2015 © Copyright - Bionova